Human organs-on-chips for disease modelling, drug development and personalized medicine

Donald E. Ingber 1,2,3

Abstract | The failure of animal models to predict therapeutic responses in humans is a major problem that also brings into question their use for basic research. Organ-on-a-chip (organ chip) microfluidic devices lined with living cells cultured under fluid flow can recapitulate organ-level physiology and pathophysiology with high fidelity. Here, I review how single and multiple human organ chip systems have been used to model complex diseases and rare genetic disorders, to study host–microbiome interactions, to recapitulate whole-body inter-organ physiology and to reproduce human clinical responses to drugs, radiation, toxins and infectious pathogens. I also address the challenges that must be overcome for organ chips to be accepted by the pharmaceutical industry and regulatory agencies, as well as discuss recent advances in the field. It is evident that the use of human organ chips instead of animal models for drug development and as living avatars for personalized medicine is ever closer to realization.

There is great interest in finding alternatives to animal testing (BOX 1), because in addition to being costly, time-consuming and ethically questionable, data from animals frequently fail to predict the results obtained in human clinical trials1,2. The lack of human-relevant preclinical models and the resulting high failure rates of therapeutics in the clinic has led to an unsustainable rise in healthcare costs as well as fewer effective drugs reaching patients. There is also increasing pressure from society and governments to find alternatives to animal testing, as evidenced by the US Food and Drug Administration (FDA) Modernization Act of 2021 and the Humane Research and Testing Act (HR 1744), which are currently moving through the US Congress. Importantly, these observations bring into question the current heavy reliance upon genetically engineered mice and other animal models that dominate basic research as well as drug development today.

Organ-on-a-chip (organ chip) microfluidic culture devices represent one of the recent successes in the search for in vitro human microphysiological systems that can recapitulate organ-level and even organism-level functions. This microfluidic form of microphysiological system comes in various sizes and shapes (Fig. 1), but they all contain hollow channels lined by living cells and tissues cultured under dynamic fluid flow. Some devices recreate organ-level structures (for example, tissue–tissue interfaces) as well as provide relevant mechanical cues (for example, breathing and peristalsis-like motions) that are necessary to faithfully model organ physiology and disease states. By fluidically coupling two or more organ chips, human ‘body-on-chips’ multi-organ systems can be created that mimic whole-body physiology as well as drug distribution and disposition. Advances in stem cell technology, such as induced pluripotent stem (iPS) cells and organoids, have enabled sourcing of patient-specific stem cells that can now be integrated and differentiated within organ chips to create patient-specific preclinical models.

Previously, the organ chip field focused on the design and engineering of these microfluidic devices, and on the experimental demonstration of their ability to replicate relevant tissue and organ functions. However, the challenge now is to move to the next level by demonstrating equivalence or superiority relative to animal models. If human organ chips are found to be superior, then in addition to reducing animal testing, they may be used to develop or select therapeutics that are personalized for individual patients, distinct genetic subpopulations or even subgroups with particular disease comorbidities, which could revolutionize clinical trials design.

In this Review, I first introduce the different types of in vitro human models and provide a brief overview of the range of microfluidic organ chip designs, including different multi-organ human body-on-chips formats. I then describe recent advances in the organ chip field that demonstrate clinical mimicry by replicating human patient responses or that have applied this technology to advance drug development and personalized medicine. I review the major hurdles that must be overcome to enable replacement of animal testing by human organ
Box 1 | Need for animal alternatives

Animal results fail to predict human responses

The pharmaceutical and biotechnology industries spend billions of dollars annually on taking a single compound from discovery at the bench to approval by the US Food and Drug Administration (FDA). A key problem is that animal testing for safety and efficacy is required for regulatory approval; however, many studies have shown that results from animal studies often do not predict results in humans. This has resulted in drugs and vaccines that successfully passed through the preclinical development pipeline, including studies in small animals or even in non-human primates, but then either failed to show efficacy (for example, tuberculosis MV85a, HIV-1 DNA/rAd5, hepatitis C vaccines) or induced potentially life-threatening toxicities (for example, HuSc8 monoclonal antibodies), thus causing cessation of human trials. Equally concerning is that there are probably drugs that could be safe and effective in humans but that have never reached clinical trials because they were dropped from development pipelines owing to erroneous results in animals.

Fundamental research insights may be skewed by use of animal models

The weak predictive power of preclinical models is particularly worrisome given the heavy emphasis on use of animals, and particularly genetically engineered mice, in basic research, which is often where potential drug targets are first identified. In fact, when researchers directly compared the predictive value of murine models of various human disorders (for example, Alzheimer disease, sepsis and acute respiratory distress syndrome), the results have been dismal. Thus, although animal models of disease may appear phenotypically similar to humans, the underlying molecular and cellular mechanisms are often distinct and potential therapeutic targets identified in these models may therefore lack clinical relevance.

New challenges require human relevant models

Therapeutics development has been transformed over the past few decades by the creation of biologic therapies through biotechnology, such as therapeutic monoclonal antibodies, adeno-associated viral gene vectors, small interfering RNAs and CRISPR RNA therapies. What is shared by all these approaches, and not by small-molecule drugs, is that some of these compounds can be so specific for human target molecular sequences or conformations that they should not show activity in non-human models or they may exhibit different activities. As biologic therapies are rapidly approaching nearly half of all drugs in development, this raises another critical need for human-relevant preclinical models.

There are other challenges that require human models. For example, one of the recent paradigm shifts in medicine has been the recognition of the central part that the microbiome plays in human health and disease. However, the complex communities of microorganisms that comprise the microbiome differ in humans versus other species, as well as between different individuals and even in the same person at different points in time or in different locations. This challenge is further complicated as it has not been possible to co-culture complex microbial communities in direct contact with human cells because this often leads to culture contamination and cell death within hours.

The need for personalized preclinical models will become even more critical as the healthcare industry shifts its emphasis towards precision medicine. For example, the finding that there is a great variability in responses to therapy among different genetic or ethnic populations, as can be observed in some clinical trials, raises the question of whether modelling human genetic disorders using inbred animal models still makes sense. Preclinical human in vitro models that contain organ-specific cells isolated from surgical samples, adult stem cell-containing organoids or induced pluripotent stem (iPS) cells derived from individual patients, could provide a way to meet these new challenges.

Clinical mimicry

Recapitulation of physiological, pathophysiological or therapeutic responses detected in the human body.

Personalized medicine

A practice of medicine that uses data obtained from an individual patient’s cells to guide decisions regarding prevention, diagnosis or treatment of disease.

Emerging human in vitro models

For the past century, living mammalian cells have been primarily cultured in nutrient medium under static conditions on 2D substrates coated with serum or extracellular matrix (ECM) molecules that were initially optimized to promote cell proliferation. Unfortunately, stimulation of cell growth is often accompanied by loss of tissue-specific functions, and thus, many in the field have questioned the physiological relevance of results from in vitro experiments. For this reason, there has been a constant interest in the design of microphysiological systems that can better sustain tissue functionality for extended times in vitro, which has led to the emergence of the microphysiological systems field.

Microphysiological systems development has progressed through combined advances in microsystems engineering, tissue engineering and stem cell biology. As a result, many microscale culture system designs have been developed that reconstitute tissue and organ functions at levels not attainable in the past. Two broad approaches to microphysiological systems development have been pursued to attain improved biological mimicry: (1) the creation of static 3D culture systems with greater structural complexity, and (2) engineering of microfluidic 3D culture devices that also incorporate dynamic fluid flow, which have come to be referred to as organ chips.

Static microphysiological systems. Static microphysiological systems models, including microengineered tissues and organoids grown within 3D ECM gels, have demonstrated an impressive ability to recapitulate tissue histogenesis and many biological functions, including drug metabolism and cytotoxicity responses, as well as to model various disease states at the cell and tissue levels. Thus, they provide powerful tools with which to dissect the molecular basis of developmental control as well as disease pathogenesis and, hence, could help to replace animal studies for particular applications. Nonetheless, they do not replicate tissue–tissue interfaces, vascular perfusion, interstitial flow, circulating immune cells or organ-specific mechanical cues that are critical for accurate mimicry of the delivery and absorption, distribution, metabolism and excretion (ADME) of pharmaceutical compounds or their pharmacokinetics and pharmacodynamics (PK/PD). Thus, static microphysiological systems are not optimal for accurate assessment of drug disposition, efficacy and toxicity within the human body. By contrast, microfluidic organ chips can provide all these functions.

Microfluidic organ chips. The first microfluidic culture device referred to as an organ chip recapitulated the organ-level (that is, multi-tissue) structures and functions of a major functional unit of a human organ, the lung alveolus. It was fabricated using a soft lithography-based manufacturing approach adapted from the computer microchip industry. This approach was inspired by a simpler device that contained a hollow channel the size of a small lung airway, which enabled the recreation of acoustically detectable sounds when liquid plugs were flowed through the channel, nearly identical to the respiratory ‘crackle’ sounds physicians listen for through a stethoscope and use to diagnose fluid on the lungs.

The lung alveolus chip is a computer memory stick-sized device composed of an optically clear,
elastomeric, polydimethylsiloxane (PDMS) material containing two parallel hollow channels separated by a porous ECM-coated membrane lined with human lung alveolar epithelial cells on one side and human vascular endothelium on the other, thereby recreating the alveolar–capillary interface (Fig. 1a). Culture medium is perfused through the endothelium-lined channel to mimic vascular perfusion, and air is introduced into the epithelial channel to mimic the air–liquid interface of the lung, which is critical for lung differentiation and function, while application of cyclic suction to hollow side chambers enables application of cyclic tissue deformations to the flexible tissue–tissue interface to mimic breathing motions. This two-channel chip design has since been modified to provide open access to one channel and to enable formation of a thicker tissue construct while still exerting cyclic mechanical strain (for example, for a skin chip)\(^{15,16}\), and it has been used by multiple groups to create microfluidic models of various organ types with fluids flowing through both channels (Table 1). Other single device and multiplexed versions have been fabricated using various methods (for example, soft lithography, physical removal of sacrificial cylindrical mandrels, injection moulding) or that replace the porous membrane with an ECM gel to support tissue–ECM, tissue–tissue interface formation or cellular ingrowth to study dynamic 3D morphogenetic processes (for example, tumour angiogenesis\(^{15–18}\) and lymphangiogenesis\(^{19}\)) (Fig. 1b–d); however, these do not enable application of mechanical deformations.

Another organ chip design developed at about the same time used a more conventional, plastic, transwell-like, multwell (12-well) format in which tissue–tissue interfaces are recreated by culturing two different human cell types (for example, hepatocytes and liver sinusoidal endothelial cells) on opposite sides of a rigid porous membrane within minibioreactor chambers\(^{20}\) (Fig. 1e). A streamlined plastic 384-well format organ chip design was also recently described and used to create an air–liquid interface\(^{21}\) (Fig. 1f). 3D printing technology has been adapted to create dynamically perfused tubular structures lined by human organ-specific cells that can be positioned precisely within printed ECM gels to recreate, for example, a proximal tubule (Fig. 1g) or the proximal tubule–microvessel interface that is responsible for solute reabsorption in the kidney\(^{22–24}\). Organ chips have also been created in which some cell layers are 3D printed and others are assembled using microengineering approaches\(^{25}\). In addition, plastic plates have been created containing a flow channel beneath open chambers that can be used alone or in combination, and cells can be either cultured directly in the chamber or on top of porous membranes within transwell inserts that are placed in the chambers (Fig. 1h).

Multi-organ human body-on-chip systems have been created to study multi-organ physiology and whole-body level drug responses by adding fluidic coupling to culture chamber bioreactors contained within the multiwell system\(^{25–28}\) (Figs 1e,2a,b) or that use robotic liquid control systems that may more easily integrate with pharmaceutical robotic pipelines to sequentially transfer fluids between multiple soft lithography-fabricated two-channel chips\(^{29}\). An arteriovenous (AV) mixing reservoir is integrated into the latter system to provide mixing of medium, thereby mimicking blood mixing in the central circulation; this reservoir enables fluid sampling that is more analogous to sampling peripheral blood in a patient (rather than measuring drug or metabolite levels in outflows of individual organ chips) (Fig. 2c). An alternative approach fluidically links multiple micro-organ bioreactor chambers within the same plate (Fig. 1e,h), with each chamber or transwell insert containing a different tissue type (for example, liver, skin, marrow, tumour, and so on), and these devices may be configured differently depending on the number of organs to be coupled\(^{30–32}\) (Fig. 2a,b). In some versions of these multi-organ systems, medium is flowed directly from one parenchymal cell type to another (for example, from liver cells in chamber 1 to skin cells in chamber 2) without or with an intervening porous membrane\(^{33–35}\) (Figs 1h,2a). More recently, body-on-chip systems have perfused medium through channels lined by endothelium that interfaces across a porous membrane with organotypic tissues in adjacent channels or chambers to better replicate vascular perfusion and transendothelial transport of drugs and metabolites in the human body\(^{36–40}\) (Fig. 2b,c).

With the explosion of interest in this field, all of these approaches and even simpler single channel microfluidic devices that only contain a single cell type have come to be referred to as organ chips. Most of these devices are optically clear and enable real-time high-resolution microscopic imaging; however, some that contain fluidically coupled mini-reactors or incorporate thick 3D-printed or engineered tissue constructs do not. Importantly, regardless of the device design, the presence of dynamic fluid flow and organ-specific mechanical cues has been repeatedly shown to promote higher levels of tissue-specific differentiation and to enhance organ-level functions, even above those displayed in static 3D organoid cultures when organoid-derived cells are used to line the chips\(^{41–43}\). In addition, because these chips are actively perfused, immune cells can be flowed through the vascular endothelium-lined channel as they are in circulating blood\(^{12,20,23–45}\). Resident immune cells can also be placed within 3D ECM gels on-chip to recreate lymphoid and haematopoietic microenvironments and, thereby, to reconstitute specialized lymphoid follicle\(^{46}\) and bone marrow\(^{47,48}\) structures and functions in vitro.

A unique advantage of microfluidic organ chips over static microphysiological systems is that oxygen gradients can be established across the tissue–tissue interface so that complex living microbiome composed of both anaerobic and aerobic bacteria can be co-cultured directly on top of human epithelium (for example, gut microbiome on intestinal epithelium), and viable co-cultures can be sustained for multiple days in vitro\(^{49}\). This is in contrast to static microphysiological systems, including organoid cultures, in which oxygen gradients can be established, but bacterial cultures can only be maintained for about 24 h before microbial overgrowth.
Clinical mimicry in organ chips

Lung. The human lung alveolus chip with two parallel microchannels separated by a microporous membrane (FIG. 1a) garnered great attention because it was the first organ chip to replicate complex integrated organ-level physiological and pathophysiological responses, rather than to simply demonstrate retention of cell- or tissue-level differentiated functions. This chip utilized an established human lung alveolar epithelial cell line (NCI-H441 or A549) interfaced with human umbilical vein endothelial cells. The study revealed that introduction of either living bacteria to mimic infection or nanoparticles to simulate inhalation of airborne smog nanoparticles into the airspace of the epithelial channel of the two-channel chip resulted in recruitment of circulating immune cells and secretion of inflammatory cytokines, as occurs in vivo, and these processes could be visualized in real-time at high resolution. Perfusion of the cancer drug interleukin-2 (IL-2) at a clinically relevant dose through the endothelium-lined channel of this chip also led to vascular leakage and filling of the air channel with interstitial fluid and thrombi, replicating the pulmonary oedema toxicity it causes in some patients.

Moreover, the ability to replicate physiological mechanical cues revealed that breathing motions enhance inflammatory reactions and increase nanoparticle absorption across the alveolar–capillary interface; these findings were not observed in static transwell cultures. Importantly, in vivo studies carried out in parallel confirmed that all of these responses are also seen in whole lung in vivo. Another lung alveolus chip lined with human lung alveolar A549 epithelial cells was used to assess cytotoxicity responses to zinc oxide nanoparticles, which are used in biopharmaceutical preparations, drug delivery and biomedical imaging. This study revealed that these nanoparticles exhibited lower toxicity when administered under dynamic flow in the lung chip compared to static conditions.

A lung alveolus chip lined with primary human lung alveolar epithelium interfaced with primary pulmonary microvascular endothelial cells has been used to model pulmonary thrombosis by flowing human whole blood through its vascular channel. This approach enabled quantitative analysis of organ-level contributions to inflammation-induced thrombosis, and recapitulated complex responses, including platelet–endothelial dynamics within individual thrombi that were nearly identical to those visualized within thrombi that formed in vivo. Analysis of thrombosis formation on-chip induced by lipopolysaccharide endotoxin also revealed that it acts indirectly by stimulating the alveolar epithelium to produce other inflammatory molecules that induce endothelium activation, such as IL-6, rather than acting directly on endothelium.

Healthy and diseased human lung airways have been modelled by populating chips with primary bronchial or bronchiolar epithelial cells obtained from healthy donors or patients with chronic obstructive pulmonary disease (COPD) and culturing them under an air–liquid interface. Chips lined with COPD epithelial cells

and cell death result. Because organ chips are usually fabricated using microengineering approaches, it is also possible to integrate various types of in-line sensors for monitoring of tissue viability and function, including real-time monitoring of oxygen levels, changes in tissue barrier integrity (for example, using integrated electrodes to measure transepithelial and/or transendothelial electrical resistance or impedance spectroscopy) and cellular electrical activity (for example, using multi-electrode arrays).

Importantly, over the past 12 years, organ chips have been used to model a broad range of human disorders and diseases across virtually all organ systems, to garner new insights into the molecular and cellular basis of various physiological and pathophysiological processes, to model various types of drug delivery approaches (for example, adeno-associated viral vectors and nanoparticles), and to recapitulate clinical responses to therapeutics, radiation, toxins and surgical implants seen in human patients (TABLE 1). Below, I summarize results from key human organ chip studies, focusing on those that provide the strongest evidence of clinical mimicry, particularly in the context of drug development and personalized medicine.
| Human organ chip | Platform | Cell types | Disorder or disease model | Clinical mimicry | Ref. |
|-----------------|----------|------------|---------------------------|-----------------|-----|
| Brain or BBB    | 2-Channel PDMS Microporous | Neuron, microglial, astrocyte, pericyte, endo (all iPS) | Parkinson disease | α-Synuclein pathology | 84 |
|                 | 2-Channel PDMS Nanoporous | Endo, pericyte, astrocyte | Inflammation | Neuroinflammation | 87 |
|                 | 2-Channel PDMS Microporous | Endo, astrocyte, neuron (all iPS) | Huntington disease, MCT8 deficiency | Blood toxicity | 86 |
|                 | 2-Channel PDMS Microporous | Endo (iPS), pericyte, astrocyte | BBB transport | Drug and antibody transport | 85 |
|                 | 3-Channel PDMS ECM gel | Endo, pericyte, astrocyte | BBB transport | Nanocarrier transport | 89 |
|                 | 2-Channel PDMS Microporous | Endo (iPS), pericyte, astrocyte | BBB transport | Drug transport | 85 |
|                 | 3-Channel PDMS ECM gel | Endo, pericyte, neural stem, fungal | Fungal meningitis | Fungal invasion of BBB | 91 |
| Blood vessel    | 1-Channel in ECM gel Plastic | Endo | Tumour endothelium transport | Nanomaterial delivery | 126 |
|                 | 1-Channel PDMS | Aortic smooth muscle (iPS) | Progeria, inflammation, mechanosensitivity | Drug efficacy | 96 |
|                 | 2-Channel PDMS Microporous | Endo | Thrombosis | mAb toxicity | 1 |
|                 | 1-Channel in ECM gel Plastic | Endo, kidney cancer (patient) | Tumour angiogenesis | mAb efficacy | 18 |
|                 | 3-Channel PDMS ECM gel | Epi, endo, cancer | Inflammation | Nanocarrier delivery | 58 |
|                 | 3-Channel PDMS ECM gel | Lymphatic endo, breast cancer | Breast cancer | Breast cancer lymphangiogenesis | 19 |
|                 | 1-Channel PDMS | Aortic smooth muscle | Aortic valve insufficiency, mechanosensitivity | Aortic valve injury, drug efficacy | 97 |
|                 | 3-Channel PDMS ECM gel | Endo, fibroblast, colorectal cancer | Colorectal cancer | Drug efficacy | 98 |
|                 | Multichannel PDMS | Aortic smooth muscle, endo, immune | Atherosclerosis, vascular stenosis | Vascular inflammation | 127 |
|                 | 1-Channel Plastic | Stromal cell, bone marrow mononuclear | Implant-associated metal accumulation in bone | Implant toxicity | 46 |
| Human organ chip | Platform | Cell types | Disorder or disease model | Clinical mimicry | Ref. |
|-----------------|----------|------------|---------------------------|------------------|------|
| Blood vessel (cont.) | 2-Channel PDMS | Haematopoietic, endo, stromal | Radiation injury, Shwachman–Diamond syndrome | Mimic drug toxicity with clinical exposure profiles | 45 |
| | ECM gel | | | | |
| Cartilage | 2-Channel PDMS | Synovial fibroblast, chondrocyte, immune, synovial fluid | Osteoarthritis | Monocyte extravasation, drug efficacy | 36 |
| | 3 ECM gel channels | | | | |
| Eye | 2-Channel PDMS | Retinal pigmented epithelial, endo | Choroidal angiogenesis | Drug efficacy | 92 |
| | 2 ECM gel channels | | | | |
| | 2-Channel PDMS | Retinal pigmented epithelial, 7 retinal (iPS org) | Retinopathy | Drug toxicity | 91 |
| | Nanoporous | | | | |
| | 2-Channel PDMS | Retinal pigmented epithelial, 7 retinal (iPS org) | Gene therapy delivery | AAV vector delivery | 128 |
| | Nanoporous | | | | |
| | 2-Channel PDMS | Epi, endo, adipocyte (stem) | Obesity | Leptin production | 58 |
| | Nanoporous | ECM gel | | | |
| | 3-Channel PDMS | Adipocyte | Obesity | Drug efficacy | 129 |
| Fat | Nanoporous | | | | |
| Heart | 1-Channel Plastic | Cardiomyocyte (iPS) | Cardiotoxicity | Drug toxicity | 51 |
| | 3D printed PDMS + plastic | Cardiomyocyte (iPS), endo (3D printed) | Heart contractility, cardiotoxicity | Drug toxicity | 24 |
| Immune system | 2-Channel PDMS | Immune, cancer (patient) | Immuno-oncology | CART cell efficacy | 100 |
| | with ECM gel | | | | |
| | 2-Channel PDMS | Immune, cancer (patient) | Immune checkpoint blockade | Drug efficacy | 99 |
| | with ECM gel | | | | |
| | 1-Channel Plastic | Surgically explanted tumour biopsy tissues (patient) | Immune checkpoint blockade | Drug efficacy | 101 |
| | 2-Channel PDMS | Lung epi, intestine epi (org), immune | Tumour-targeted T cell bispecific Ab toxicity | mAb toxicity | 37 |
| | Microporous | | | | |
| | 2-Channel PDMS | Immune | Immunization, vaccination | Vaccine and adjuvant efficacy | 44 |
| | with ECM gel | | | | |
| Small intestine | 2-Channel Plastic | Epi (line), bacteria | Host–microbiome interactions, hypoxia gradient | Effects of microbiome metabolites on host | 72 |
| | Nanoporous | | | | |
| | 2-Channel PDMS | Epi (line) | Enteric virus infection | Infection-associated injury | 130 |
| | Microporous | | | | |
| | 2-Channel PDMS | Epi (line), endo, lymphatic endo, immune, bacteria | Bacterial infection, inflammation | Inflammatory bowel disease, probiotic drug delivery, ileus | 43 |
| | Microporous | | | | |
| Human organ chip (cont.) | Platform | Cell types | Disorder or disease model | Clinical mimicry | Ref. |
|-------------------------|----------|------------|---------------------------|------------------|-----|
| Small intestine         | 2-Channel PDMS Microporous | Epi (line), endo | Radiation injury | Radiation toxicity, drug efficacy | 75 |
|                         | 3-Channel ECM gel | Epi (org), immune | Inflammatory bowel disease | Inflammation-associated gene expression | 131 |
|                         | 2-Channel PDMS Microporous | Epi (org), endo | Intestinal differentiation | Transcriptome profile | 36 |
|                         | 2-Channel PDMS Microporous | Epi (line and org), endo | Host–microbiome interactions, hypoxia gradient | Complex microbiome–host interactions | 47 |
|                         | 2-Channel PDMS Microporous | Epi (line), endo, virus | SARS-CoV-2 virus infection | Infection-associated injury, inflammation | 21 |
|                         | 2-Channel PDMS Microporous | Epi (org), endo, immune, virus | Enteric virus infection | Drug efficacy, inflammation | 70 |
|                         | 2-Channel PDMS Microporous | Epi (org) | Environmental enteric dysfunction | Clinical phenotype and nutritional dependency | 76 |
| Colon                   | 2-Channel PDMS Microporous | Epi (org) | Bacterial infection, microbiome | Species-specific sensitivity to Escherichia coli infection | 73 |
|                         | 2-Channel PDMS Microporous | Epi (org), bacteria | Bacterial infection, mechanosensitivity | Shigella infection | 74 |
|                         | 2-Channel PDMS Microporous | Epi (org) | Inflammation, mechanosensitivity | Mucus layer formation | 69 |
|                         | 2-Channel PDMS Microporous | Epi (org), endo | Inflammation, bacterial growth | Human milk oligosaccharide effects on gut barrier | 133 |
|                         | 2-Channel PDMS Microporous | Epi (org) | Inflammatory bowel disease | Inflammation-associated injury | 133 |
| Kidney tubule           | 2-Channel PDMS Microporous | Epi | Renal transport, nephrotoxicity | Renal reabsorption, drug toxicity | 77 |
|                         | 3D printed in ECM gel | Epi | Renal transport, nephrotoxicity | Renal reabsorption, drug toxicity | 22 |
|                         | 2-Channel PDMS Nanoporous | Epi | Viral infection | Replication of clinical phenotype | 78 |
|                         | 3D printed in ECM gel | Epi, endo | Renal transport, hyperglycaemia | Renal reabsorption, drug efficacy | 23 |
|                         | 2-Channel Plastic ECM gel | Epi | Lowe syndrome, Dent II disease | Replication of clinical phenotype | 79 |
### Table 1 (cont.) | Human disease states and clinical responses replicated in single organ chips

| Human organ chip | Platform | Cell types | Disorder or disease model | Clinical mimicry | Ref. |
|-----------------|----------|------------|---------------------------|------------------|------|
| Kidney glomerulus | 3-Channel Plastic ECM gel | Epi (line) | Nephrotoxicity | Drug toxicity and transport | 134 |
| | 2-Channel PDMS Nanoporous | Endo (line), podocyte (line) | Hypertensive nephropathy, mechanosensitivity | Replication of clinical phenotype | 80 |
| | 2-Channel PDMS Microporous | Endo, podocyte (iPS) | Filtration barrier | Urinary clearance, drug toxicity | 81 |
| | 3-Channel Plastic ECM gel | Endo, podocyte | Filtration barrier, autoimmune toxicity | Drug toxicity | 83 |
| | 2-Channel PDMS Microporous | Endo (iPS), podocyte (iPS) | Personalized drug testing | Drug toxicity | 82 |
| Liver | 2-Channel PDMS Microporous | Hep | Metabolism-dependent toxicity | Drug toxicity | 65 |
| | 2-Chamber Plastic Microporous | Hep | Inflammation effects on drug metabolism | Drug metabolism, clearance | 62 |
| | 2-Chamber Plastic Microporous | Hep, Küpffer | CYP450 metabolism, drug–drug interactions | Drug metabolism, mAb–drug interactions | 63 |
| | 2-Chamber Plastic Microporous | Hep | Drug metabolism | Drug metabolism, patient variability | 64 |
| | 1-Channel Plastic | Hep, endo | Steatosis | Drug toxicity | 135 |
| | 1-Channel Plastic | Hep | Drug- and toxin-induced liver injury | Drug metabolism and toxicity | 136 |
| | 1-Channel Plastic | Hep, Küpffer | Virus (Hepatitis B) infection, inflammation | Viral infection-associated injury | 67 |
| | 2-Channel PDMS Microporous | Hep, endo, hepatic stellate, Küpffer | Drug-induced liver injury | Human and cross species drug toxicities | 66 |
| | 3-Channel Plastic ECM gel | Hep, endo, hepatic stellate, Küpffer | Nonalcoholic steatohepatitis | Drug efficacy | 137 |
| | 2-Channel Plastic ECM gel | Hep (iPS), endo, immune | Hepatotoxicity | Drug toxicity screen, high throughput | 120 |
| | 2-Channel PDMS Microporous | Hep, endo, hepatic stellate, Küpffer | Drug-induced liver injury | Replicate human drug toxicities | 118 |
| Lung alveolus | 2-Channel PDMS Microporous | Epi (line), endo, immune | Inflammation, mechanosensitivity | Breathing-dependent nanoparticulate toxicity | 31 |
| Human organ chip (cont.) | Platform | Cell types | Disorder or disease model | Clinical mimicry | Ref. |
|--------------------------|----------|------------|---------------------------|------------------|-----|
| Lung alveolus            | 2-Channel PDMS Microporous | Epi (line), endo | Pulmonary oedema | Drug toxicity | 52 |
|                          | 2-Channel PDMS Microporous | Epi, endo | Thrombosis | Drug efficacy | 54 |
|                          | 2-Channel PDMS Microporous | Epi, endo, cancer | Non-small cell lung cancer | Site-specific and mechanosensitive tumour growth, drug efficacy | 57 |
|                          | 2-Channel PDMS Microporous | Epi, endo | Pulmonary oedema, gene therapy delivery | AAV vector delivery, drug efficacy | 58 |
|                          | 3-Channel PDMS ECM gel | Epi, endo, cancer | Lung cancer | Drug efficacy | 56 |
|                          | 2-Channel PDMS Microporous | Epi (line), endo, immune | Virus infection (SARS-CoV-2), inflammation | Drug efficacy | 41 |
|                          | 2-Channel PDMS Microporous | Epi, endo | Virus infection (influenza, SARS-CoV-2, MERS-CoV), inflammation | RNA therapy efficacy | 60 |
|                          | 2-Channel PDMS Microporous | Epi, endo | Virus infection (influenza), inflammation, mechanosensitivity | Drug efficacy against viral inflammation | 59 |
|                          | 1-Channel PDMS | Epi (line) | Nanoparticle delivery and toxicity | Nanoparticle toxicity | 53 |
| Lung airway              | 1-Channel PDMS | Epi | Mechanical injury to airway cells | Reproduction of respiratory crackle sound | 32 |
|                          | 2-Channel PDMS Nanoporous | Epi, endo, immune | Asthma, COPD | Inflammation, COPD exacerbations, drug efficacy | 39 |
|                          | 2-Channel PDMS Nanoporous | Epi | COPD exacerbation by smoke inhalation | Replication of clinical phenotype | 55 |
|                          | 2-Chamber Plastic Nanoporous | Epi | Glucocorticoid metabolism, mucus production | Drug metabolism & clearance | 139 |
|                          | 2-Channel PDMS Microporous | Epi, endo, immune, bacteria | Cystic fibrosis, inflammation, bacterial infection | Hyperinflammation in cystic fibrosis | 40 |
|                          | 2-Channel PDMS Microporous | Epi, endo, cancer | Non-small cell lung cancer | Site-dependent cancer growth | 57 |
|                          | 2-Channel PDMS Microporous | Epi, immune | Asthma exacerbation by virus infection | Drug efficacy | 56 |
|                          | 2-Channel PDMS Microporous | Epi, endo, immune | Virus infection (influenza, pseudotyped SARS-CoV-2), inflammation | Drug repurposing, drug efficacy | 42 |
exhibited selective cytokine hypersecretion, increased neutrophil recruitment and mimicked clinical exacerbation by exposure to viral and bacterial infections as well as cigarette smoke. Transcriptomic profiles of healthy airway chips exposed to cigarette smoke closely resembled those obtained in past clinical studies. In addition, models of the asthmatic lung airway were developed by exposing healthy airway chips to IL-13, which induced goblet cell hyperplasia, inflammatory cytokine secretion and endothelial activation, while reducing cilia beating frequency, all of which are observed in asthmatic patients.

Table 1 (cont.) | Human disease states and clinical responses replicated in single organ chips

| Human organ chip | Platform | Cell types | Disorder or disease model | Clinical mimicry | Ref. |
|------------------|----------|------------|--------------------------|-----------------|-----|
| Lung airway (cont.) | 2-Channel PDMS Microporous | Epi, endo | Virus infection (influenza, SARS-CoV-2, MERS-CoV), inflammation | RNA therapy efficacy | 60 |
| | 2-Channel PDMS Microporous | Epi, endo | Virus evolution (influenza) | Resistance to drug therapy | 61 |
| | 2-Channel Plastic Nanoporous | Epi | Virus infection (SARS-CoV-2, HCoV-NL63, influenza), inflammation | Viral infectivity, inflammation, high throughput | 21 |
| Mammary gland | 2-Channel in an ECM gel | Epi, endo | Breast cancer | Mutation-induced cancer progression, angiogenesis | 94 |
| Nerve | 2-Channel PDMS Microporous | Spinal neuron, endo (iPS) | Vascular–neuronal interactions | Neuronal maturation | 140 |
| | 3-Channel Plastic ECM gel | Neuron | Motor neuron injury | Drug toxicity and efficacy | 141 |
| Pancreas | 1-Channel Plastic | Whole isolated pancreatic islets | Diabetes mellitus | Glucose-sensitive insulin secretion | 141 |
| Placenta | 2-Channel PDMS Microporous | Trophoblast (line), endo | Placental barrier | Drug transport | 95 |
| Skin | 2-Chamber Plastic Nanoporous | Keratinocyte | Skin irritation | Drug and chemical toxicity | 141 |
| Teeth | 3-Channel PDMS Dentin fragment | Dental stem, dentin | Dental material toxicities | Biomaterials toxicity | 144 |
| | 3-Channel PDMS Dentin fragment | Dental stem, dentin, bacteria | Biofilm formation | Biomaterials efficacy | 145 |
| Uterus | 2-Channel PDMS Microporous | Epi, stromal | Endometrial remodelling | Uterine contraception, drug efficacy | 146 |
| | 5-Channel PDMS 2 ECM gels | Epi, endo, stromal | Endometrial remodelling | Menstrual cycle-dependent endometrial differentiation | 147 |

Platform indicates the device design, including channel or chamber configuration (including number), material composition (polydimethylsiloxane (PDMS) or plastic), porosity of intervening membrane (microporous or nanoporous), whether a channel is filled with an intervening extracellular matrix (ECM) gel, or whether the microfluidic channel is formed within an ECM gel. All cells are primary cells unless indicated as follows: established cell line (line); chips lined with organotypic cells derived from human induced pluripotent stem cells (iPS); patient-derived primary cells (patient); patient organoid-derived cells (org); cells isolated from organoids derived from iPS cells (iPS org); stem cells (stem); or cells deposited with 3D printing (3D printed). All cells are human except for the microbial cells mentioned. AAV, adeno-associated virus; BBB, blood–brain barrier; COPD, chronic obstructive pulmonary disease; CoV, coronavirus; endo, vascular endothelial cell; epi, epithelial cell; hep, hepatocyte; mAb, monoclonal antibody; MCT8, monocarboxylate transporter 8; neuron, brain neuronal cell.

Cilia
Moving microscopic hair-like projections found on the surfaces of cells, such as lung airway epithelial cells, that cause motions in overlying fluids or mucus.
Fig. 2 | Schematics showing different multi-organ human body-on-chips formats. a | A simple fluidic coupling between multiple chambers lined by different organotypic cell types and a common flow chamber in two-chamber organ chip designs; a porous membrane within each chamber separates the overlying cell type from the fluid flow path or transwell inserts containing cells may be placed within open chambers as shown in Fig. 1h. To mimic intravenous (IV) administration, the drug can be introduced into the lower flow path. b | A similar multiwell configuration, except that the surface of the shared flow chamber is lined by endothelium. c | A diagram of linked two-channel organ chips containing both parenchymal cells and an endothelium-lined flow channel that are fluidically coupled using a robotic liquid handler to transfer fluids drop-by-drop between the chips and an arteriovenous mixing reservoir. The reservoir is integrated into the system to mimic blood mixing in the central circulation, and it also allows fluid sampling that is more analogous to sampling peripheral blood in a patient. Red arrows indicate the directional fluid flow or transfer path, and the circled ‘I’ depicts points in the circuit that is more analogous to sampling peripheral blood in a patient. Red arrows indicate points in the circuit that is more analogous to sampling peripheral blood in a patient. Red arrows indicate the directional fluid flow or transfer path.

This recruitment response was greater than observed in a static transwell microphysiological system. More recently, lung airway chips have been used to model the cystic fibrosis airway by incorporating primary epithelium isolated from patients with cystic fibrosis. These chips accurately replicate many features of the human cystic fibrosis airway, including increases in cilia density, mucus accumulation, ciliary beating frequency and IL-8 secretion, leading to greater adhesion of circulating immune cells to the endothelium and their transmigration into the airway compartment compared to healthy chips. The cystic fibrosis chips also provided a more favourable environment for growth of Pseudomonas aeruginosa bacteria and an enhanced inflammatory response, both of which are major contributors to morbidity in patients with cystic fibrosis.

The ability of lung alveolus and airway chips lined by primary cells to support growth of human non-small-cell lung adenocarcinoma cells has also been studied. The cancer cells grew much more rapidly in the alveolus chip, which faithfully recapitulated the preferential growth at this site seen in patients with this type of cancer. Interestingly, the ability to control mechanical cues revealed that breathing motions suppress cancer growth and invasion in the lung, and that they alter the efficacy of a first-line anticancer drug (rociletinib). A more sophisticated version of this device, containing three parallel channels with an ECM gel lined with endothelial cells and fibroblasts that supports formation of 3D branching microvascular networks, enabled analysis of the response of human lung adenocarcinoma cells to clinically relevant concentrations of the chemotherapy drug paclitaxel and demonstrated both tumour and endothelial cell toxicities.

A human immunocompetent lung alveolus chip containing primary lung cells and peripheral blood mononuclear cells was used to assess the safety of T cell bispecific antibody cancer therapies. These chips effectively reproduced non-human primate (NHP) toxicities of T cell bispecific antibodies targeting folate receptor 1 that are currently under clinical development. Importantly, when a lower-affinity T cell bispecific antibody that was found to exhibit lower toxicity in the lung chip was tested in NHPs, none of the animals experienced the lung inflammation observed with the original higher-affinity antibody, thus confirming the safer profile predicted by this human organ chip. Currently, one of the most clinically relevant uses of human lung chips is in the study of respiratory virus infections. For example, infection of a lung alveolus chip lined by an established alveolar epithelial cell (HPAEpiC) line interfaced with a lung endothelial cell (HULEC-5a) line with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed preferential infection of the epithelium and stimulation of distinct innate immune responses in these two tissues, as well as recruitment of circulating immune cells, which led to endothelial detachment and further increased inflammatory cytokine release. Treatment with remdesivir inhibited viral replication and alleviated barrier compromise on-chip. Human lung airway chips containing primary bronchial epithelium and pulmonary endothelium also recapitulated viral infection, cytokine production and recruitment of circulating immune cells, as well as virus strain-dependent virulence observed in human patients when infected with various influenza A virus strains. Use of the model led to the discovery that co-administration of the anti-coagulant drug nafamostat with the first-line antiviral drug oseltamivir doubled oseltamivir’s treatment-time window. Moreover, when these chips were infected with...
a pseudotyped SARS-CoV-2 virus and perfused with clinically relevant doses of the antimalarial drugs chloroquine or hydroxychloroquine, these drugs were found not to be active, thus predicting the negative results seen in clinical studies. By contrast, a related drug, amodiaquine, was shown to actively inhibit SARS-CoV-2 pseudovirus virus entry on-chip, as well as infection by native infectious SARS-CoV-2 in a hamster model. Importantly, these results contributed to the repurposing of this drug and its entry into clinical trials for COVID-19 in Africa, where this drug is used widely for antimalarial prophylaxis.

Another recent example of drug repurposing comes from use of the mechanical control capabilities of the primary lung alveolus chip, which revealed that physical forces associated with cyclic breathing motions influence lung innate immune responses to viral infection\(^\text{59}\). This work led to the discovery that receptor for advanced glycation end products (RAGE), an inflammatory mediator that is most highly expressed in the lung alveolus in vivo, has a central role in this response. Moreover, when a RAGE inhibitor drug (azeliragon) was tested, it potently suppressed production of inflammatory cytokines and synergized with the antiviral drug molnupiravir in this model. These results were included in a recent submission of a pre-IND (Investigational New Drug) meeting application to the FDA to request initiation of clinical trials to test whether azeliragon can suppress the cytokine storm in patients with COVID-19. Use of lung alveolus and airway chips also led to the discovery of a new class of broad-spectrum RNA therapeutics that induce a potent type I interferon response and inhibit infection by SARS-CoV2, SARS-CoV, MERS-CoV, HCoV-NL63 (a common cold virus) and multiple influenza A virus strains\(^\text{60}\).

Virus evolution through both mutation and gene reassortment as seen in patients with influenza has also been reconstituted in vitro by sequentially passaging infected mucus droplets between multiple human lung airway chips infected with influenza H1N1 in the continued presence of the antiviral drugs amantadine or oseltamivir (also known as Tamiflu)\(^\text{61}\). This selective pressure led to the spontaneous emergence of clinically prevalent resistance mutations as well as previously unobserved strains. Interestingly, strains that were resistant to both drugs also emerged; however, studies revealed that they were still sensitive to the anticoagulant nadroparin, which targets host serine proteases.

Liver. Multiple liver chip designs have been developed and used to model drug metabolism, drug–drug interactions, hepatotoxicity, inflammation and infection (TABLE 1). A microfluidic liver chip with the multwell bioreactor design (FIG. 1) lined by primary human hepatocytes and Kupffer cells replicated breakdown of the glucocorticoid hydrocortisone to phase I and phase II metabolites, and the intrinsic clearance values measured on-chip correlated with human data\(^\text{62}\). This selective pressure led to the spontaneous emergence of clinically prevalent resistance mutations as well as previously unobserved strains. Interestingly, strains that were resistant to both drugs also emerged; however, studies revealed that they were still sensitive to the anticoagulant nadroparin, which targets host serine proteases.

Liverchip created by combining microfabrication and 3D elecrophysiological responses in real time\(^\text{51}\). This chip mimicked the difference in safety profiles between the cardiotoxic pro-drug terfenadine and its non-toxic metabolite fexofenadine seen in patients. Another heart chip created by combining microfabrication and 3D
Printing that contains human iPS-cell-derived cardiomyocytes interfaced with endothelial cells reproduced the toxic effects of the cancer drug doxorubicin on heart myocardium observed clinically.

Intestine. Numerous organ chip models of the small and large intestine lined by intestinal epithelial cells with or without underlying endothelium have been created to model various diseases as well as to study drug metabolism and toxicities (Table 1). The presence of dynamic fluid flow has been found to be necessary and sufficient to promote villi formation in small intestine chips as well as production of high numbers of goblet cells and accumulation of a thick mucus bilayer in colon chips, which closely resemble those in living intestine using the two-channel chip design (Fig. 1a); however, additional application of peristalsis-like mechanical motions is required for optimal differentiation.

Moreover, when lined with duodenal or colon organoid-derived epithelial cells, these mechanically active microfluidic chips more closely resemble human small and large intestine than organoids cultured in static microphysiological systems (either 3D ECM gel or transwell cultures) based on transcriptomic and histological characterization. In a study on infection with an enteric coronavirus (NL63), organoid-derived intestinal epithelial cells were found to also dramatically increase their ACE2 receptor levels when cultured under flow in the presence of peristalsis-like mechanical deformations in two-channel microfluidic intestine chips compared to when cultured statically as organoids in 3D gels or in transwell inserts.

A two-channel human intestine chip lined by Caco-2 intestinal epithelial cells interfaced with endothelium was used to study SARS-CoV-2 infection and to reconstitute the morphological, structural and inflammatory changes consistent with gastrointestinal symptoms observed in patients with COVID-19.

The human intestine–microorganism interface was modelled in a two-channel microfluidic chip lined by established intestinal epithelial cell lines (Caco-2 or CRL-1459 cells), which recreates an oxygen gradient supporting the growth of a single commensal obligate anaerobe (Lactobacillus rhamnosus GG); this co-culture modified transcriptional, metabolic and immunological host responses in a manner similar to that previously observed in vivo. However, the microorganisms had to be separated from the host epithelium by a nanoporous membrane in this chip and so only the effects of transported soluble mediators could be studied.

More recently, a living complex gut microbiome containing more than 200 different living bacterial species with similar complexity to a human stool microbiome was co-cultured in direct contact with human intestinal epithelial and its naturally secreted mucus layer for 5 days within two-channel intestine chips lined by either Caco-2 cells or primary human organoid-derived epithelium interfaced with primary intestinal microvascular endothelium. This was accomplished by establishing a hypoxia gradient across the epithelial–endothelial interface that mimics the one existing in vivo, which was confirmed using integrated on-chip oxygen sensors, and intestinal barrier function was either maintained or enhanced by the presence of living bacteria. By contrast, exposure of small intestine chips lined by Caco-2 intestinal cells interfaced with primary microvascular endothelium to pathogens can induce inflammation, cause cell death and disrupt the intestinal permeability barrier, as observed clinically in patients with inflammatory bowel disease. Use of a human colon chip lined by organoid-derived epithelium in combination with metabolomics was also used to identify specific microbial metabolites that mediate species-specific (human versus mouse) differences in sensitivity to enterohaemorrhagic Escherichia coli infection. Interestingly, cessation of cyclic mechanical deformations results in bacterial overgrowth and epithelial injury in the small intestine chip, hence mimicking the clinic disorder known as ileus, which is caused by intestinal paralysis (for example, due to prolonged anaesthesia). By contrast, the presence of dynamic fluid flow and active peristalsis-like cyclic deformations enhance Shigella infection and invasion in a colon chip. It is important to note that none of these mechanobiological behaviours can be detected in static microphysiological systems, and bacteria cannot be co-cultured in these static models for more than about 24 h without inducing cell death.

An intestine chip model of acute radiation injury also replicated the same radiation dose sensitivity observed in humans, which differs from that observed in animal models. Radiation exposure induced reactive oxygen species production primarily by the endothelium, which resulted in epithelial cytotoxicity, apoptosis and DNA fragmentation, as well as disruption of tight junctions, villus blunting and compromise of the intestinal barrier; pre-treatment with a potential prophylactic radiation countermeasure drug (dimethylxaloylglycine) suppressed these responses in this model.

An inflammatory condition of the intestine that is endemic in children in low-resource nations, known as environmental enteric dysfunction (EED), was recently modelled in human intestine chips. Key features of this disease, including villus blunting, compromised intestinal barrier function and reduced nutrient absorption, as well as impairment of fatty acid uptake and amino acid transport, were reconstituted in two-channel chips lined by intestinal epithelial cells isolated from EED patient-derived organoids when the cells were cultured in nutrient-deficient medium. These culture conditions led to transcriptional changes similar to those observed in clinical EED patient samples from multiple low-resource nations. Human intestine chips lined by organoid-derived cells and perfused with peripheral blood mononuclear cells also have been used to reproduce and predict clinical toxicities of a T cell bispecific antibody currently under clinical development that targets human carcinoembryonic antigen so specifically that neither its safety nor efficacy can be evaluated in animal models.

Kidney. Kidney chips lined by human renal tubular or glomerular cells have been used for studies on drug and molecule transport, reabsorption and toxicity as well as disease modelling (Table 1). For example, a two-channel...
kidney chip lined by primary proximal tubular epithelium that expressed high P-glycoprotein efflux transporter activity replicated a transporter-specific cisplatin toxicity that is observed in patients but not in static 2D cultures or animal models. Albumin reabsorption and cyclosporine toxicity were also recapitulated in a 3D-printed kidney chip containing human proximal tubular epithelium deposited within tiny cylindrical structures surrounded by a thick ECM gel. This approach was extended further by printing closely apposed kidney tubules and vessels lined by proximal tubular epithelium and kidney endothelium within an ECM gel, which exhibited active reabsorption via tubular–vascular exchange of solutes similar to that observed in vivo. Hyperglycaemia-induced endothelial cell dysfunction was replicated in this model, as well as its reversal by administration of a glucose transport inhibitor drug. Moreover, a kidney distal tubule chip was used to explore pathogenesis of Pseudorabies virus-induced renal dysfunctions. Virus infection resulted in altered sodium reabsorption, disruption of the reabsorption barrier and changes in microvilli, which may contribute to the serum electrolyte abnormalities observed in virus-infected patients.

Importantly, a kidney proximal tubule chip also replicated phenotypic features of two rare X-linked monogenic diseases (Lowe syndrome and Dent II disease), which are characterized by renal reabsorption defects caused by mutations in the *OCRL* gene. Knocking down *OCRL* expression in the cells revealed that proximal tubule cells lacking OCRL upregulate collagen deposition, which can contribute to the interstitial fibrosis and disease progression seen in these disorders.

Use of a human kidney glomerulus chip containing closely opposed layers of immortalized kidney podocytes and glomerular endothelial cells revealed that glomerular mechanical forces play a crucial part in cell damage that leads to increased glomerular leakage, as observed in patients with hypertensive nephropathy. Another glomerulus chip lined by human iPS-cell-derived podocytes interfaced with glomerular endothelium reconstituted in vivo levels of urinary clearance and mimicked the toxic effects of the anticancer drug adriamycin on kidney podocytes. More recently, a personalized version of this to toxic effects of the anticancer drug adriamycin on kidney in vivo levels of urinary clearance and mimicked the

In a recent study, the human neurovascular unit was modelled in a microfluidic chip containing a perfused channel lined by endothelium interfaced with pericytes adjacent to a 3D ECM gel containing astrocytes and neurons derived by in situ differentiation of human neural stem cells. This chip was used to model brain infection by the fungus *Cryptococcus neoformans* and revealed that clusters of the fungal cells penetrate the BBB without altering tight junctions, suggesting a transcytosis-mediated mechanism as well as providing a testbed in which to develop novel therapeutics.

**Eye.** An eye chip that reconstituted the outer retinal–choroid barrier containing human retinal pigmented epithelium adjacent to a perfusable 3D blood vessel network was able to recreate the choroidal neovascularization associated with wet macular degeneration by demonstrating penetration of the retinal pigmented epithelial monolayer by angiogenic sprouts that extended from pre-existing choroidal vessels. This pathological
angiogenesis was inhibited by the monoclonal therapeutic antibody bevacizumab, which is used clinically for this condition.

Furthermore, a retina chip was developed containing more than seven different retinal cell types, all derived from human iPS cells, which provided vascular perfusion and recapitulated interactions of mature photoreceptor segments with retinal pigmented epithelium. In addition to mimicking the formation of outer segment-like structures and establishing in vivo-like physiological processes of the eye (for example, outer segment phagocytosis and calcium dynamics), this organ chip reproduced the clinical retinopathic toxicities of chloroquine and gentamicin.

**Bone.** A bone chip containing human mesenchymal stromal cells, osteoblasts and bone marrow mononuclear cells embedded within human de-cellularized bone was used to model the release of dissolved metals (cobalt and chromium) from arthroplasty implants, which can lead to peri-implant bone loss. Indeed, both metals were found to integrate into bone matrix in this 3D model in a manner also seen in patient bone samples.

A bone marrow chip was created by incorporating human donor-derived CD34+ haematopoietic cells from marrow or bone and bone-marrow-derived stromal cells in a 3D ECM gel separated from a neighbouring endothelium-lined channel. This chip reconstituted differentiation and maturation of multiple blood cell lineages over 1 month in culture and replicated myeloid toxicities in response to clinically relevant exposures to the cancer therapeutic 5-fluorouracil as well as to γ-radiation. Even more impressively, it was able to replicate regimen-specific toxicities of a cancer drug observed in human clinical trials when the drug exposure (pharmacokinetics) profiles previously measured in patients were recreated on-chip. And again, these responses were not observed when the same haematopoietic cells were placed in static cultures. In addition, personalized bone marrow chip models of a rare genetic disorder, Shwachman–Diamond syndrome (SDS), were created in this study using CD34+ cells obtained from patients with SDS. These cells replicated key haematopoietic defects seen in patients and led to the discovery of a previously unknown neutrophil maturation abnormality in a subpopulation of these patients.

**Reproductive organs.** A mammary gland chip lined by mammary duct epithelium cultured in an ECM gel in close proximity to a perfused endothelium-lined vessel underwent branching morphogenesis on-chip. Impressively, this chip was able to reproduce duc tal changes associated with invasive cancer progression by amplifying HER2 (also known as ERBB2) receptor expression or expressing constitutively active PI3Kα in non-tumorigenic mammary epithelium using retroviral vectors.

A placenta chip lined by trophoblast cells interfaced with endothelial cells was used to screen drugs for their ability to cross the placenta. This model reconstituted the efflux transporter–mediated active transport function of the human placental barrier, which serves to limit fetal exposure to maternally administered drugs, using the gestational diabetes mellitus drug glyburide.

**Blood vessels.** Organ chip models of large and small blood vessels have been used to study various vascular disorders, including inflammation, thrombosis and atherosclerosis, as well as to model vascular contributions to numerous diseases (Table 1). Notably, a blood vessel chip lined by vascular endothelium and perfused with human whole blood reproduced the clinical thrombotic toxicity of a therapeutic monoclonal antibody drug (Hu5c8) that had been previously withdrawn from clinical trials owing to unexpected life-threatening complications that were not detected during preclinical animal testing. This model was also used to validate the lower thrombotic risk of an improved version of a related antibody that incorporates an Fc domain that does not bind the FcyRIa receptor.

Hutchinson–Gilford progeria syndrome is a premature ageing disease characterized by accelerated death due to cardiovascular disease, particularly involving mechanically active blood vessels. When a progeria blood vessel chip was developed using vascular smooth muscle cells derived from iPS cells of patients with progeria, it exhibited exacerbated inflammation and DNA damage in response to mechanical strain compared to chips lined with cells from healthy donors. Interestingly, this physical stress-induced injury could be reversed by administering two drugs, lovastatin and lonafarnib, which are often used clinically for this disease.

An aorta chip was used to study the development of the more common congenital disorder aortic valve disease. Chips lined by aortic vascular smooth muscle cells isolated from patients exhibited suppressed NOTCH1 expression and impaired mitochondrial dynamics, and genetic knockdown of NOTCH1 in healthy smooth muscle cells suppressed mitochondrial fusion and reduced contractility. Use of this model revealed that the mitochondrial fusion activator drugs leflunomide and teriflunomide can partially rescue the mitochondrial dynamics disorder in these diseased cells.

Some of the vascular applications that have been most pursued using human organ chip technology focus on the study of angiogenesis, inflammation and the role of neovascularization in a wide range of diseases, as well as transendothelial transport and delivery of nanomaterials (Table 1). For example, by incorporating 3D ECM gels into one microfluidic channel, nearby endothelium can be stimulated to extend capillary sprouts in a directional manner; if endothelia are cultured in two parallel channels separated by ECM, the invasive sprouts will meet, differentiate into hollow tubes and form a fully perfused 3D capillary network. Recently, this approach was adapted to demonstrate endothelial sprouting induced by primary human patient-derived renal cell carcinoma cells from multiple donors that exhibited patient-specific patterns of angiogenic factor production. A similarly vascularized tumour chip revealed that gene expression, tumour heterogeneity and therapeutic responses observed on-chip more closely model colorectal tumour clinicopathology than do current standard
drug screening modalities, including 2D cultures and 3D spheroids\(^7\). A three-channel microfluidic device that mimics the vascular–tissue–lymphatic interface has also been developed to study lymphangiogenesis associated with cancer metastasis\(^8\).

**Lymphoid organs.** Inflammatory reactions including recruitment and activation of immune cells, release of pro-inflammatory cytokines, tissue barrier disruption and cell injury have been reproduced in many organ chips (Table 1). However, it is possible to model more complex human immune responses using organ chip technology as well. A lymphoid follicle chip was recently developed that cultures peripheral blood-derived primary human blood B and T lymphocytes within a 3D ECM gel in one channel while flowing medium through a parallel channel\(^9\). Superfusion in this manner prevents the lymphocyte autoactivation observed in conventional cultures and promotes the formation of germinal centre-like structures that contain B cells that undergo antibody class switching and plasma cell differentiation upon activation with antigens. When autologous monocyte-derived dendritic cells were integrated into the gel and the chips were inoculated with a commercial influenza vaccine, increases in follicle size and number, plasma cell formation, production of anti-haemagglutinin IgG antibodies and secretion of cytokines similar to those observed in vaccinated humans were detected over clinically relevant timescales.

Organ chips have also been used to evaluate immunotherapies, including personalized therapies when used with patient-derived cells. For example, small-molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) were identified as potential novel immune checkpoint inhibitors using a chip in which patient-derived tumour cell spheroids containing autologous infiltrating immune cells were cultured within 3D ECM gels surrounded by microfluidic channels\(^10\). These CDK4/6 inhibitors augmented the response to PD-1 blockade, thus providing a rationale for combining these agents with other immunotherapies to enhance therapeutic efficacy.

The tumour microenvironment imposes significant constraints on the antitumor efficacy of adoptive T cell immunotherapy, which cannot easily be modelled in conventional cultures. To address this challenge, human liver cancer cells were cultured in an organ chip inside a 3D ECM gel, and human T cells engineered to express tumour-specific T cell receptors (TCRs) T cells were flowed through an adjacent channel\(^11\). The TCR T cell ability to migrate and kill tumour targets was analysed, as well as the influence of varying levels of oxygen and inflammatory cytokines. This approach could be used in the future to design and evaluate personalized cellular immunotherapies, for example, using 3D-printed organ chips containing patient-derived tumour biopsy samples that enable real-time monitoring of the responses of resident lymphocyte populations\(^12\).

**Multi-organ physiological coupling and drug PK/PD modelling.** One of the challenges in drug development that most pharmaceutical scientists assume is likely not to be solved in the near term is the need for animal testing to assess drug disposition (for example, ADME) in the whole body and to quantify PK/PD parameters that help to guide clinical trial design. Although animal models may still be required for these purposes for some years to come, recent work suggests that many of these complex whole-body physiological responses may be modelled in vitro using fluidically coupled multi-organ human body-on-chips systems. Multi-organ chip models developed so far, which may have from 2 to 10 different organ chips, have provided impressive mimicry of complex physiological and pathophysiological responses in addition to providing new in vitro tools with which to assess drug ADME and PK/PD (Table 2).

In one impressive example of complex physiological mimicry, dynamic inter-organ hormonal coupling and the 28-day menstrual cycle were reconstituted in vitro by fluidically linking human organ chip models of uterus, cervix, fallopian tube and liver to a mouse ovary chip and recirculating the medium\(^13\). Coupled organ chip systems have also been used to model multi-organ regulation of insulin secretion\(^10,14,15\); metastatic spread of cancer between different organs\(^16,17\); targeted immune responses to organ-specific damage\(^18,19\), and the toxic effects of environmental chemicals that required hepatic bioactivation\(^20\), including activation of germ cell toxins in linked liver and testis chips\(^21\).

The most common application of multi-organ chip systems has been to replicate the absorption (for example, oral or transdermal), distribution and clearance of drugs through metabolism or excretion that naturally occur in the organs of our body, but which are absent in single organ chips or other in vitro models (Table 1). Small-molecule and biologic drug efficacies, as well as both on- and off-target toxicities that can be modified by inter-organ interactions (via hepatic activation or metabolism), have been demonstrated too, and the results generated generally agree with published human data\(^22,23,24,25\). In addition, organ chips have been coupled to assess drug efficacy and safety simultaneously. For example, by measuring the effects of anti-EGFR therapeutic monoclonal antibodies in a lung cancer chip while analysing toxicity in a fluidically coupled skin chip, it was possible to replicate the inhibition of keratinocyte growth and altered expression of CXCL8 and CXCL10 seen in patients\(^26\). As another example, a clinically relevant drug–drug interaction between the arrhythmogenic gastroprokinetic drug cisapride and the fungicide ketoconazole was reproduced using a liver chip linked to a heart chip when both were lined by cells derived from the same human iPSC cell line\(^27\), which shows the potential of using organ chips to optimize therapeutics selection in a personalized manner.

Microfluidic systems composed of multiple culture chambers in which medium is flowed directly from one parenchymal cell compartment to another via a single channel have been used to carry out PK/PD modeling in vitro for many years, although established cell lines were usually used in early studies\(^28\). Later versions separated the flow chamber from the culture chambers with an intervening porous membrane or used transwell inserts as culture chambers\(^29,30\) (Fig. 2a). A body-on-chip
or chambers, as occurs in our bodies13,31,32,34,35. Channels that are separated from parenchymal channels constitute medium through endothelium-lined vascular linked by flowing or transferring a common blood substitute medium through endothelium-lined vascular channels that are separated from parenchymal channels.

Chips lined by primary human cells that are fluidically linked by flowing or transferring a common blood substitute medium through endothelium-lined vascular channels that are separated from parenchymal channels were consistent with clinical data112. This type of modelling has been carried out in organ-on-a-chip systems of this type composed of linked liver, kidney, intestine, skeletal muscle and BBB chips generated predictions of drug metabolism and barrier penetrance that were consistent with clinical data112. But it is only recently that this type of modelling has been carried out in organ-on-a-chip systems of this type composed of linked liver, kidney, intestine, skeletal muscle and BBB chips along with an AV reservoir in combination with computational modelling by flowing or transferring a common blood substitute medium through endothelium-lined vascular channels that are separated from parenchymal channels or chambers, as occurs in our bodies13,31,32,34,35. This more physiologically relevant approach has been used in combination with computational modelling to generate predictions of drug PK/PD parameters and toxicities in many studies (Table 2).

| Coupled human organ chips | Whole-body response | Clinical mimicry | Ref. |
|---------------------------|---------------------|------------------|------|
| Liver + skin              | Inter-organ molecular crosstalk | Albumin production–utilization | 29   |
| Liver + intestine         | Inter-organ inflammatory crosstalk | Inflammation exacerbation | 28   |
| Liver + intestine and liver + skin | Drug absorption | Oral and transdermal drug absorption | 32   |
| Liver + intestine         | Cancer metastasis | Inter-organ metastatic spread | 105  |
| Liver + heart + nerve + muscle | Multi-organ toxicity | Drug toxicity | 106  |
| Liver + intestine         | PK analysis | PK modelling | 26   |
| Liver + pancreas          | Diabetes mellitus | Glucose-induced insulin secretion | 30   |
| Liver + kidney            | Nephrotoxicity | Xenobiotic metabolism | 105  |
| Liver + lung + heart (3D printed) | Drug disposition | Drug efficacy, toxicity and metabolism | 107  |
| Liver + uterus + cervix + Fallopian tube + ovary (mouse) | Reproductive hormonal regulation | Human menstrual cycle | 25   |
| Liver + intestine + kidney + BBB + muscle | Drug disposition and toxicity, PK analysis | Drug PK, metabolism | 112  |
| Liver + intestine + lung + endometrium + brain + heart + pancreas + skin + kidney + muscle | PK analysis | Drug PK analysis | 27   |
| Skin + lung cancer        | Lung cancer | mAb therapy efficacy and toxicity | 110  |
| BBB + brain               | Drug disposition in brain | Drug toxicity | 34   |
| Liver + heart + breast + bone marrow + vulva cancer | Breast, bone marrow and vulva cancers | Drug efficacy, toxicity and metabolism | 108  |
| Liver + intestine + lung + brain + heart + pancreas + skin + kidney + muscle + BBB | PK analysis | Drug PK | 13   |
| Liver + intestine + kidney + bone marrow | PK/PD analysis, IVIVT | Drug PK/PD and toxicity, predictive IVIVT | 35   |
| Heart + bone cancer       | Metastatic cancer, cardiotoxicity | Drug toxicity and efficacy | 109  |
| Liver + testis            | Reproductive toxicity | Liver metabolism of steroids, testis toxicity | 31   |
| Liver + heart + skeletal muscle + immune cells | Immune response to tissue damage | Tissue-targeted immune response | 104  |
| Liver (iPS) + pancreas (iPS) | Diabetes mellitus, metabolic disease | Glucose-sensitive insulin secretion | 102  |
| Liver (iPS) + heart (iPS)  | Drug–drug interactions | Drug–drug interactions, drug toxicity | 111  |
| Liver + intestine + kidney + brain (all iPS) | Personalized multi-organ chip system | Body-on-chips with same donor-derived cells | 113  |

iPS indicates chips lined with organotypic cells derived from human induced pluripotent stem (iPS) cells. BBB, blood–brain barrier; IVIVT, in vitro to in vivo translation; mAb, monoclonal antibody; PD, pharmacodynamics; PK, pharmacokinetics.

system of this type composed of linked liver, kidney, intestine, skeletal muscle and BBB chips generated predictions of drug metabolism and barrier penetrance that were consistent with clinical data112. But it is only recently that this type of modelling has been carried out in organ-on-a-chip systems of this type composed of linked liver, kidney, intestine, skeletal muscle and BBB chips along with an AV reservoir in combination with computational modelling by flowing or transferring a common blood substitute medium through endothelium-lined vascular channels that are separated from parenchymal channels or chambers, as occurs in our bodies13,31,32,34,35. This more physiologically relevant approach has been used in combination with computational modelling to generate predictions of drug PK/PD parameters and toxicities in many studies (Table 2). For example, it has been possible to quantitatively predict human clinical pharmacokinetics parameters using a multi-organ chip first-pass model composed of linked two-channel human liver, kidney and intestine chips along with an AV reservoir in combination with computational modelling by flowing or transferring a common blood substitute medium through endothelium-lined vascular channels that are separated from parenchymal channels or chambers, as occurs in our bodies13,31,32,34,35. This more physiologically relevant approach has been used in combination with computational modelling to generate predictions of drug PK/PD parameters and toxicities in many studies (Table 2). For example,
As these body-on-chip systems are modular, the chips can be linked either in series or in parallel, and the flow can be either unidirectional or recirculated.

What will it take to replace animal models?

The question of what will be required to enable eventual acceptance of human organ chips in lieu of preclinical animal models, their integration into drug development...
pipelines, and inclusion of data generated using these models in FDA regulatory submissions is a complex one\textsuperscript{115-117}. One point that is clear is that this process will probably occur gradually and involve replacement of one particular animal model at a time. To meet this goal, pharmaceutical companies and regulatory agencies will require rigorous demonstration of equivalent or superior performance relative to animal models. This goal will require definition of specific validation methods and performance criteria in addition to successful completion of statistically well powered validation studies that demonstrate that a specific organ chip model can generate human-relevant results in a reproducible and statistically robust manner regardless of where the work is carried out. Because only small numbers of organ chips are used in most academic studies, and different groups use different device configurations and methodologies, true validation of their use as animal replacements will require large-scale evaluation involving hundreds of devices of the same design carried out using the same protocols. Thus, this problem will not be solved by academic researchers publishing more research or even establishing design standards at the community level. Instead, this will probably be decided on the commercial battlefield, which is now possible given that there are many companies manufacturing organ chips as well as automated control systems to run them\textsuperscript{115,116}.

A key challenge is to identify the critical design criteria and performance parameters that must be met to qualify an organ chip model as functional at a level necessary for adoption by pharmaceutical and biotechnology companies as well as regulatory agencies\textsuperscript{115}. This will require commercial chip suppliers to demonstrate reliability, robustness and consistency in terms of cell sourcing as well as to define performance and quality control expectations precisely for every step in the execution and analysis of these model systems. Importantly, all interested parties recognize that there is no way to pursue replacement of animal models in a generalized way, and instead that each organ chip must be validated for a specific commercial ‘context of use’ (for example, drug safety, drug efficacy, toxicology, ADME characterization, PK/PD modelling). However, each organ chip must also be validated for a particular physiological context of use. For example, a lung alveolus chip with epithelium and endothelium might be useful for studying efficacy of drugs in pharmacology studies relating to pulmonary oedema, but a different chip also containing fibroblasts would be required to model pulmonary fibrosis.

Commercial adoption is likely to occur in a staged or stepwise manner by identifying applications that can overcome existing barriers in the pharmaceutical industry workflow, for example, by validating that human organ chips can successfully replace existing animal models that are known to be suboptimal and lead to failures in the clinic (for example, rodent and dog liver toxicity assays). But as their predictive power is increasingly validated over time, they should be integrated into other early stages of the drug development pipeline, including being used for drug discovery and lead target validation as well as for the optimization and prioritization of lead compounds, or for the identification of alternate leads when safety issues arise (FIG. 4). For example, organ chips lined by patient-derived cells would be particularly useful when toxicities are observed in a particular patient subpopulation in phase I trials (for example, women versus men, or a genetically similar subgroup); if the toxicity could be replicated on chip, this would provide a valuable tool with which to identify other related active compounds in the pipeline that do not exhibit this toxicity. There is also increasing recognition of the need to create organ chip models made with cells from other species (for example, rodents, dogs or NHPs) to generate benchmark comparison data that could help pharmaceutical companies and vaccine developers to validate results obtained in these models relative to results obtained in past in vivo studies, and thus become more comfortable with integrating organ chips into their development processes\textsuperscript{115}. Although the initial goal in these efforts might be to demonstrate equivalence or superiority to a particular animal model, the ultimate benchmark for success should be the replication of existing in vivo human clinical data.

On a more pragmatic level, organ chips are generally more expensive than conventional cultures, and so to be accepted, the improvement in performance they offer must be equally great. However, given the level of human clinical mimicry that they can potentially provide, animal models might be a more appropriate comparator in terms of costs and complexity of use. In this context, it is important to note that a survey of pharmaceutical companies estimated that microphysiological systems could save their industry up to about 25% in research and development costs\textsuperscript{115}. Another recent analysis suggests that even the replacement of one animal model by an organ chip for a single context of use, such as drug-induced liver toxicity, could generate the industry US$3 billion annually owing to increased productivity\textsuperscript{118}. Importantly, because the organ chip industry is in its infancy, the cost of chips and the instruments required to run them should also progressively decrease over time, owing to economies of scale.

To meet these challenges and harness these benefits, international organizations composed of experts from the pharmaceutical and biotechnology industries, such as the microphysiological systems affiliate of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Consortium, have proposed approaches to be followed to qualify organ chips and other microphysiological systems to ensure their acceptance in lieu of animal models by the industry and, hopefully, by regulatory agencies\textsuperscript{1}. These requirements include obvious ones, such as following good laboratory practice (GLP) regulations and developing strategies to validate and document the functionality, reliability and robustness of cell sources, devices, instruments, experimental protocols and analytical procedures. But they have also established specific performance metrics for particular applications, such as prediction of drug-induced liver injury (DILI), which includes testing of specific drug compounds that
have known safety records in animals and humans\textsuperscript{119}. These types of studies are important because they can be used to quantitatively assess the predictive performance of organ chips and compare those predictions to both human clinical data and past animal results. The FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot programme, which has established similar qualification programmes for drug development tools, including organ chips, now also offers a defined path to expedite their acceptance for regulatory use. One positive sign for the field is that a recent report describes an analysis involving almost 800 human liver chips created with cells from two different donors that successfully met the IQ consortium’s DILI qualification guidelines across a blinded set of over 27 known hepatotoxic and non-toxic drugs with a sensitivity of up to 87% and a specificity of 100%, demonstrating a major improvement in performance relative to animal models\textsuperscript{118}.

**Future opportunities and challenges**

The advances described above demonstrate that human organ chips can be used to address many types of questions in human biology and medicine that could not be addressed using prior culture systems or even many static microphysiological systems. For example, whereas static 3D organoid cultures have many advantages (for example, they provide patient-specific insights, exhibit highly differentiated behaviours, and are easy to multiplex for higher-throughput studies), they cannot provide many of the critical functions offered by organ chips, including direct quantification of barrier function, digestion and absorption; the creation of an air–liquid interface; the physiological recruitment of circulating immune cells; the application of physiological mechanical cues and fluid shear stress; sustained co-culture with a complex microbiome; replication of tissue responses to clinically relevant drug exposure profiles with delivery of drugs and chemicals across an endothelial...
barrier; or the prediction of human drug pharmacokinetics parameters. However, these two technologies are clearly synergistic, because organ chips lined by patient organoid-derived cells offer some of the most powerful in vitro preclinical models available today. Even more importantly, as described above, organ chips have been repeatedly shown to mimic human pathophysiology and predict human clinical responses to therapeutics better than animal models do, and hence the bar has been raised when it comes to relying on animal-testing data. Notably, the use of healthy and diseased human organ chip models for toxicity and efficacy testing represents a major advantage over existing testing approaches that use inbred healthy animals (BOX 1). Also, exploring the variation of results obtained using organ chips made with cells from different patient donors, from individuals from defined genetic subpopulations, or even patients with different comorbidities (that is, other ongoing chronic disorders), might better replicate the diversity of in vivo clinical data, and may help to both facilitate clinical trial design and improve success. In addition, their ability to support extended co-culture of human cells with a complex living microenvironment provides a tool with which to analyse host-microorganism interactions as well as to test potential probiotic or prebiotic therapies in a human-relevant context. Moreover, when fluidically coupled to create human body-on-chips systems, they can potentially provide a testbed for pharmaceutical scientists to analyse complex drug disposition, ADME and PK/PD behaviours, in addition to enabling basic scientists to study complex inter-organ interactions (for example, menstrual cycle or metastatic cancer spread). This could have real clinical value: for example, the ability to quantitatively predict human drug PK/PD parameters in vitro could be used to optimize dose regimens for new therapeutics and thereby shorten phase I clinical trials.

Organ chips can be particularly useful for applications when it is difficult to carry out studies in humans (for example, effects of potentially lethal radiation exposures), when preclinical testing needs to be carried out using biologics that do not recognize non-human targets, or when a genetic disease cannot be modelled using other approaches (FIG. 4). The ability to build chips with patient-derived cells also opens up new approaches for therapeutic development, particularly for patients with rare genetic disorders. Organ chips provide a more human-relevant alternative to animal models such as genetically engineered mice that do not faithfully replicate human physiology or disease states, yet that still dominate basic research and drug development today. Perhaps more importantly, given the difficulty in gathering enough patients with a rare disorder together at a single site for clinical study, it could provide a way to carry out a preliminary human trial on chips using cells obtained from patients around the world to optimize drug candidate selection before initiating full trials. One can also imagine using organ chips lined by female versus male cells to circumvent the current lack of female individuals in human clinical trials, to compare young versus old cells to carry out paediatric trials on chips, or to test drugs on subpopulations of patients with similar comorbidities, given the difficulty in doing this in the clinic (FIG. 4). Also, as it is very difficult to carry out safe clinical trials in pregnant women, the ability to study drug and toxin passage across the placental barrier on-chip could provide a valuable new preclinical model for drug developers.

The COVID-19 pandemic has brought to the fore the need for new ways to accelerate drug repurposing and discovery during viral outbreaks, and human organ chips have been successfully used to confront this challenge. The recently developed lymphoid follicle chip that recapitulates germinal centre formation, plasma cell generation, antigen-specific antibody class switching and relevant cytokine production offers a potential human-relevant replacement for the NHP models currently used to test vaccines or drugs, which do not always predict results in humans and are severely limited in availability owing to the COVID-19 pandemic. In addition, the ability to model virus evolution using lung airway chips offers the possibility of predicting new strains before they emerge, which could accelerate development of both drugs and seasonal vaccines for various viruses (for example, influenza, SARS-CoV-2 variants) in the future. Given the ability of organ chips to reproduce human bacterial infections in tissues from both healthy individuals and patients with chronic diseases (for example, cystic fibrosis), and to mimic fungal infections as well, similar approaches may be used for the discovery of antibiotics for emerging antibiotic-resistant organisms.

In the short term, the use of organ chips lined by mouse, rat, dog, NHP and other animal cells could help to validate the approach, garner acceptance by pharmaceutical and academic scientists and provide a way to confront One Health challenges, for example, by developing animal models to study how disease vectors arise before they reach humans (for example, SARS-CoV-2 infection in bat organ chips). However, based on recent progress in this field using iP5 cells (TABLE 1), it is now possible to imagine a future in which single organ chips or multi-organ chip systems fabricated using organotypic cells from the same patient could be used as personalized living avatars to repurpose or select more effective and less toxic therapeutics, optimize delivery routes and design dose regimens for that specific patient, thereby opening up a new path in precision medicine (FIG. 4). Such an approach will be costly, and so an earlier step might be to create chips lined with primary or stem cells from patients representing unique genetic subpopulations and to use these chips to develop or select new drugs for particular groups, then carry out clinical trials using these patients (FIG. 4). This mid-term approach could shorten the time, decrease the cost and increase the likelihood of success in the drug development process.

Although organ chip technology has much to offer, there are still technical, social and economic hurdles that must be overcome before we see significant numbers and types of animals being replaced. Sourcing of high-quality human cells is always a great challenge, but this is now less of a problem given the availability of iP5 cells and organoids. Most organ chips are also
low throughput, but high content; this can be valuable at later stages in the drug development pipeline (for example, where selection of lead compounds must be made for drug advancement), but not in the earlier discovery phase. Higher-throughput systems are needed to enable practical implementation of statistically significant studies with many replicates, which is essential for pharmaceutical validation, and indeed, the recent development of higher-throughput organ chips (that is, single devices containing many parallel culture chambers) that still retain many of the key features required for drug developers\cite{1,2} (TABLE 1) suggest that this path should be pursued as well. However, this goal also can be met by developing automated instruments that can culture and analyse multiple lower-throughput organ chips simultaneously.

Human organ chips have been created using primary cells derived from human donors from commercial suppliers, established cell lines and patient-derived organoids or iPS cells (TABLE 1). Although the prevailing view is that use of established lines is not ideal from the standpoint of in vitro to in vivo correlation and that the use of primary cells or patient-derived cells is clearly preferred, cell lines could be valuable for particular applications as long as the model is experimentally validated by demonstrating successful mimicry of in vivo human responses relevant to the specific context of use. This is because cell lines can provide a virtually unlimited supply of similar cells that can enable higher-throughput studies and potentially enhance the reproducibility of results, which may be extremely valuable for early phases of drug development. While iPS cells offer the same advantage, they can be limited by their frequent inability to exhibit a fully mature differentiated phenotype. However, if chips lined by cell lines are used, confirmatory follow-up studies would then need to be carried out with a smaller set of lead compounds using organ chips lined by primary cells.

Another potential limitation is the prevailing concern that the PDMS polymer used to fabricate many organ chips cannot be used effectively for drug studies owing to drug absorption\cite{3}; however, this has not turned out to be as serious a concern as originally assumed. Significant absorption by PDMS is observed only with highly hydrophobic drugs, which represent a subset of small-molecule therapeutics, and the reality is that more than 40% of drugs in current development pipelines are biologics (for example, therapeutic antibodies or RNA therapeutics) that do not have these issues. Mitigation strategies, such as computational correction of the absorption effect by quantifying drug levels using mass spectrometry have been described, which circumvent this problem for most drugs (for example, as demonstrated in testing of 27 different small-molecule drugs, including hydrophobic compounds)\cite{15}. In fact, most of the organ chip studies reviewed here used PDMS devices (TABLE 1), and this includes those that demonstrated in vivo mimicry in response to clinically relevant drug exposures and that enabled quantitative prediction of human pharmacokinetics parameters\cite{13,16}. Nevertheless, it is true that for a small number of highly hydrophobic compounds (for example, sex steroids), absorption into PDMS remains a complicating factor. This limitation can be circumvented by coating PDMS with non-absorptive coatings\cite{17}, using alternative flexible elastomeric materials that are less absorptive (for example, certain polyurethanes, styrenic block copolymers, polycarbonate-thermoplastic elastomer hybrids\cite{18,19} or by using rigid thermoplastics that are non-absorptive (for example, polystyrene or polycarbonate)\cite{20}.

Perhaps the biggest challenge we face is a conceptual one: many pharmaceutical, regulatory and academic researchers have much invested in the ways they carry out research at present, and they may be wary of changing their ways; convincing data that demonstrates the advantages of human organ chips over animal models will be needed before they accept this new technology into their laboratories. Nonetheless, with the help of groups such as the IQ Consortium and the FDA\cite{21,22}, there are now benchmarks that must be met to validate the use of human organ chips as animal replacements, and the first advances are being seen in this area. As a result, we are now at a tipping point in this field, with the possibility of seeing real reductions in the use of animals and the application of more effective approaches for drug development and personalized medicine as well as basic research in the near future.

Published online 25 March 2022

1. Fabre, K. et al. Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications. Lab Chip 20, 1049–1057 (2020).
2. Golding, H., Khurana, S. & Zaitseva, M. What is the predictive value of animal models for vaccine efficacy on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications. Lab Chip 20, 1049–1057 (2020).
3. Barrile, R. et al. Organ-on-chip recapitulates thrombosis induced by an anti-CD154 monoclonal antibody: translational potential of advanced microengineered systems. Clin. Pharmacol. Ther. 104, 1240–1248 (2018).
4. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507–3512 (2013).
5. Franco, R. & Cedazo-Minguez, A. Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans? Front. Pharmacol. 5, 146 (2014).
6. Zhang, B. et al. Advances in organ-on-a-chip engineering. Nat. Rev. Mater. 3, 257–278 (2018).
7. Chen, Y. et al. Advances in engineered three-dimensional (3D) body urothelial unit models. Drug Des. Dev. Ther. 16, 213–255 (2022).
8. Victor, I. A., Andem, A. B., Archibong, I. A. & Iwok, E. O. Interplay between cell proliferation and cellular differentiation: a mutually exclusive paradigm. Cytob. Gen. Sci. J. B. 1528–1538 (2020).
9. Ghallab, A. A. A. In vitro test systems and their limitations. EXCLI J. 12, 1026–1026 (2013).
10. Clevers, H. Modeling development and disease with organoids. Cell 165, 1586–1597 (2016).
11. Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662–1668 (2010).
12. Huh, D. et al. Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in microfluidic airway systems. Proc. Natl Acad. Sci. USA 104, 18886–18891 (2007).
13. Novak, R. et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat. Biomed. Eng. 4, 407–420 (2020).
14. Varone, A. et al. A novel organ-chip system emulates three-dimensional architecture of the human epithelia and the mechanical forces acting on it. Biomaterials 275, 120957 (2021).
15. Nguyen, D. H. et al. Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro. Proc. Natl Acad. Sci. USA 110, 6712–6717 (2013).
16. Trietsch, S. J., Israëls, G. D., Joore, J., Hankemeier, T. & Vulto, P. Microfluidic titer plate for stratified 3D cell culture. Lab Chip 13, 5548–5554 (2013).
17. Phan, D. T. T. et al. A vascularized and perfused organ-on-a-chip platform for large-scale drug screening applications. Lab Chip 17, 511–520 (2017).
18. Miller, C. P., Tsuchida, C., Zheng, Y., Himmelfarb, J. & Aklesh, S. A 3D human renal cell carcinoma-on-a-chip for the study of tumor angiogenesis. Neoplasia 20, 610–620 (2018).
19. Cho, Y. et al. Three-dimensional in vitro lymphangiogenesis model in tumor microenvironment. Front. Bioeng. Biotechnol. 9, 697657 (2021).
20. Domansky, K. et al. Perfused multicell plate for 3D liver tissue engineering. Lab Chip 10, 51–58 (2010).
21. Gard, A. L. et al. High-throughput human primary cell-based assay model for evaluating influenza, coronavirus, or other respiratory viruses in vitro. Sci. Rep. 11, 14961 (2021).
22. Hoeschen, K. A. et al. Bioprinting of 3D convoluted renal proximal tubules on perfusable chips. Sci. Rep. 6, 34845 (2016).
23. Lin, N. Y. C. et al. Renal reabsorption in 3D vascularized proximal tubule models. Proc. Natl Acad. Sci. USA 116, 5399–5404 (2019).
24. Zhang, Y. S. et al. Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. Biomaterials 110, 45–59 (2016).
25. Xiao, S. et al. A microfluidic culture model of the kidney glomerular-capillary-wall function on a chip. Nat. Commun. 6, 14588 (2017).
26. Shuler, M. L., Ghanem, A., Quick, D., Wong, M. C. & Odijk, M. et al. Measuring direct current trans-epithelial electrical resistance in organ-on-a-chip Microsystems. Lab Chip 15, 745–752 (2015).
27. Ortega-Prieto, A. M. et al. 3D microfluidic liver cultures recapitulating human inter-tissue crosstalk. Sci. Rep. 8, 45390 (2018).
28. Chen, W. L. K. et al. Integrated gut/liver microphysiological systems for quantitative in vitro pharmacokinetic and pharmacodynamic studies. AAPS J. 19, 1499–1512 (2017).
29. Kim, H. J., Li, H., Collins, J. J. & Ingber, D. E. Gut-on-a-chip models key features of viral-induced exacerbation of asthma. Sci. Transl. Med. 5, 190ra47 (2012).
30. Arathi, A., Joseph, X., Akhil, V. & Mohanan, P. V. I-Cysteine cappend zinc oxide nanoparticles induced cellular response on adenocarcinomic human alveolar basal epithelial (A549) cell line in a microfluidic organ-on-a-chip approach. Colloids Surf. B 211, 112500 (2021).
31. Jain, A. et al. Human liver alveolus on a chip model of intravascular thrombosis for assessment of therapeutics. Clin. Pharmacol. Ther. 105, 352–340 (2018).
32. Benam, K. H. et al. Matched-comparative modeling of normal and diseased human airway responses using a microengineered lung-breathing lung chip. Cell Syst. 3, 456–466.e4 (2016).
33. Vatine, G. D. et al. Human iPSC-derived blood–brain barrier chip recapitulates human barrier function and countermeasure drug responses in a human brain-chip to assess blood–brain barrier dysfunction. Nat. Commun. 10, 5866 (2019).
34. Si, L. et al. Modeling therapeutic antibody–small molecule drug–drug interactions using a three-dimensional perfusable human liver coculture platform. Drug Metab. Dispos. 43, 1091–1095 (2015).
35. Long, T. J. et al. Modeling therapeutic antibody–small molecule drug–drug interactions using a three-dimensional perfusable human liver coculture platform. Drug Metab. Dispos. 44, 1940–1948 (2016).
36. Si, L. et al. Quantitative assessment of population variance on drug metabolism using a perfused three-dimensional human liver microphysiological system. J. Pharmacol. Exp. Ther. 360, 595–602 (2016).
37. Lee, P. J., Hung, P. J. & Lee, L. P. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepaticocyte culture. Biotechnol. Bioeng. 97, 1540–1546 (2007).
38. Jung, K.-J. et al. Modeling nanocarrier transport and cellular response in an adenocarcinomic human alveolar basal epithelial cell line in a microfluidic organ-on-a-chip. BioRxiv 83, 0069 (2017).
39. Brown, J. A. et al. Metabolic consequences of inflammatory disruption of the blood–brain barrier in an organ-on-chip model of the human neurovascular unit. J. Neuroinflammation 13, 506 (2016).
40. Sahito, D. et al. Transferase receptor targeting by de novo sheet extension. Proc. Natl Acad. Sci. USA 118, e2021569118 (2021).
41. Lee, S. W. L. et al. Microvascular carrier transport across a 3D in vitro human blood–brain barrier microvasculature. Adv. Health. Mater. 10, e1901486 (2021).
42. Morad, G. et al. Tumor-derived extracellular vesicles breach the intact blood–brain barrier via transcytosis. ACS Nano. 13, 1588–1600 (2019).
43. Kim, J. et al. Fungal brain infection modelled in a human-neurovascular-unit-on-a-chip with a functional blood–brain barrier. Nat. Biomed. Eng. 5, 850–864 (2021).
44. Chung, M. et al. Wet-AMD on a chip: modeling outer retinal injury in vitro. Adv. Health. Mater. 7, 1700028 (2018).
45. Achberger, K. et al. Merging organoids and organ-on-a-chip technology to generate complex multi-layer tissue models of human retina-on-a-chip platform. eLife 8, e46188 (2019).
46. Kuty, M. L. et al. Uncovering mutation-specific morphologic phenotypes in colorectal cancer, recapitulating clinical bone marrow toxicities and patient-specific pathophysiology. Nat. Biomed. Eng. 4, 396–406 (2020).
47. Schoen, J. et al. Metal-specific biomaterial accumulation in human peri-implant and bone marrow. Adv. Sci. 7, 2000412 (2020).
48. Fajun, Fajun, H., Zheng, F. & Osseiran, A. Metal-specific biomaterial accumulation in human peri-implant and bone marrow. Adv. Sci. 7, 2000412 (2020).
49. Lin, Y. C., Li, H., Wang, M. C. & Ingber, D. E. Placental endothelial barrier microenvironment induces human intestinal cells to undergo epithelial-mesenchymal transition. Integr. Biol. 5, 1130–1140 (2013).
50. Sontheimer-Pheils, A. et al. Human colon-on-a-chip enables continuous in vitro analysis of colon mucus layer accumulation and physiology. Cell Mol. Gastroenterol. Hepatol. 9, 507–526 (2020).
51. Bein, A. et al. Enteric coronavirus infection and treatment model with an immunocompetent human intestine-on-a-chip. Front. Pharmacol. 12, 718484 (2021).
52. Guo, Y. et al. SARS-CoV-2 induced inflammatory responses with a human gut-on-chip. Sci. Bull. 66, 785–793 (2021).
53. Shah, P. et al. A microfluidics-based in vitro model of the gastrointestinal human-microbe interface. Nat. Commun. 11, 15555 (2020).
54. Towagari, A. et al. Species-specific enhancement of enterohepmonic C. coli pathogenesis mediated by microbiome metabolites. BMCMicrobe 7, 65 (2019).
55. Grassart, A. et al. Bioengineered human organ-on-chip reveals intestinal microphysiological systems for quantitative in vitro drug testing. Cell Host Microbe 26, 435–444.e4 (2019).
56. Jala, J. et al. Modeling radiation injury and countermeasure drug responses in a human gut-on-a-chip. Cell Death Dis. 9, 225 (2018).
57. Bein, A. et al. Nutritional deficiency recapitulates intestinal injury associated with environmental enteric disease in patient-derived Organ-Chips. Preprint at medRxiv https://doi.org/10.1101/2021.11.21.21267238.
Hachey, S. J. et al. An in vitro vascularized aortic aneurysm in bicuspid aortic valve disease. *eLife* 10, e69510 (2021).

Deng, J. et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. *Cancer Discov.* 8, 216–233 (2018).

Alessi, V. et al. A 3D microfluidic model for predictive evaluation of TCR-engineered T cells against solid tumors. *JCI Insight* 2, e89762 (2017).

Beckwith, A. L., Velásquez-García, L. F. & Borenstein, J. T. Microfluidic model for evaluation of immune checkpoint inhibitors in human tumors. *Adv. Healthc. Mater.* 8, e1900289 (2019).

Tao, T. et al. Microengineered multi-organoid system from hiPSCs to recapitulate human liver- islet axis in normal and type 2 diabetes. *Adv. Sci.* 9, 2103495 (2022).

Skardal, A. et al. Multi-organoid interactions in an integrated three-organ-on-a-chip platform. *Sci. Rep.* 7, 8837 (2017).

Sassenath, T. T. et al. Differential monocye actuation in a three-organ functional innate immune system on- a-chip. *Adv. Sci.* 7, 2000323 (2020).

Chang, S. Y. et al. Human liver–kidney model mimicking multichannel system for recapitulating vascular stenosis and inflammation. *Micromachines* 12, 1528 (2021).

Achberger, K. et al. Human stem cell-based retina on chip as new translational model for validation of AvA retinal gene therapy vectors. *Stem Cell Rep.* 16, 2242–2256 (2021).

Bagley, A. F. et al. Endothelial thermoderivator impairs nanoparticle transport in tumors. *Cancer Res.* 75, 3255–3267 (2015).

Cho, M. & Park, J. K. Modular 3D in vitro artery-mimicking multichannel system for recapitulating vascular stenosis and inflammation. *Micromachines* 12, 1528 (2021).

Domsary, K. et al. Clear castable polyurethane elastomer for fabrication of microfluidic devices. *Lab Chip* 13, 3956–3964 (2013).

Domansky, K. et al. SEBS elastomers for fabrication of microfluidics with reduced drug absorption by injection molding and extrusion. *Microfluid. Nanofluid.* 21, 107 (2017).

Schreiner, S., Böck, E. J. S., Schneider, O., Schlünder, K. & Loskill, P. Facile patterning of thermoplastic elastomers and robust bonding to glass and thermoplastic microfluidic cell culture and organ-on-chip. *Micromachines* 12, 575 (2021).

Borenstein, J. T. Microfluidic model for evaluation of efficacy and off-target toxicity of anticancer therapeutics. *Micromachines* 12, 695 (2021).

Cho, H. W. & Gom, Y. B. Forensic analysis of human microbiome in skin and body fluids based on geographic location. *Front. Cell. Infect. Microbiol.* 11, 695191 (2021).

Fogel, D. B. Factors associated with clinical trials that fail and failures for improving the likelihood of success: a review. *Contemp. Clin. Trials* Commun. 11, 156–164 (2018).

Acknowledgements

The author thanks all of the research team members, trainees, collaborators and other members of the scientific community for contributing to the development of the organ chip field. The author’s work discussed here was funded by grants from DARPA, FDA, NIH, BARDA, Cancer Research United Kingdom and the Gates Foundation.

Competing interests

D.E.I. holds equity in Emulate, chairs its scientific advisory board and is a member of its board of directors.

Peer review information

*Nature Reviews Genetics* thanks Jeffrey T. Borenstein, YongTae Kim and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.